Antineoplastic AgentsNeoplasmsChemotherapy, AdjuvantCell Line, TumorAntineoplastic Combined Chemotherapy ProtocolsDrug Resistance, NeoplasmApoptosisMedical OncologyTreatment OutcomeBreast NeoplasmsLung NeoplasmsSEER ProgramDrug Screening Assays, AntitumorMice, NudeDoxorubicinCell ProliferationNeoplasm StagingCisplatinCell CycleRadiation, IonizingRadiation DosageAntineoplastic Agents, PhytogenicRadiation InjuriesSignal TransductionAntibiotics, AntineoplasticCombined Modality TherapyEtoposideCell SurvivalAge FactorsDose-Response Relationship, RadiationDrug Delivery SystemsRadiation ToleranceUnited StatesPaclitaxelXenograft Model Antitumor AssaysTumor Cells, CulturedDrug CarriersRadiationCohort StudiesCamptothecinCyclophosphamideRetrospective StudiesDose-Response Relationship, DrugRadiation ProtectionInhibitory Concentration 50EllipticinesDrug Resistance, MultipleRadiation MonitoringP-GlycoproteinAntimetabolites, AntineoplasticDrug SynergismOrganoplatinum CompoundsDNA DamageMolecular StructureVinblastineDrug DesignDaunorubicinAntineoplastic Agents, AlkylatingBleomycinProdrugsPlatinumMethotrexateTime FactorsMitomycinGene Expression Regulation, NeoplasticTaxoidsDisease-Free SurvivalDNA Topoisomerases, Type IIMitoxantroneColonic NeoplasmsRadiotherapyCarboplatinPlant ExtractsSurvival AnalysisNeoadjuvant TherapyEnzyme InhibitorsDrug Administration ScheduleTopoisomerase I InhibitorsDeoxycytidineRadiation-Sensitizing AgentsAdenocarcinomaNanoparticlesDrug Evaluation, PreclinicalNanomedicinePrognosisAnthracyclinesClinical Trials as TopicRadiation OncologyOvarian NeoplasmsTumor Suppressor Protein p53Gamma RaysSurvival RateMolecular Targeted TherapyNeoplasm TransplantationCaspasesProto-Oncogene Proteins c-bcl-2NanocapsulesDrug DiscoveryBrain NeoplasmsNeoplasms, Experimental